Apr 2, 2026 7:00 am EDT Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Mar 10, 2026 4:01 pm EDT Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 5, 2026 7:00 am EST Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Feb 2, 2026 7:00 am EST Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Jan 29, 2026 7:00 am EST Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Jan 5, 2026 7:00 am EST Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Nov 10, 2025 4:01 pm EST Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update